Ellipta Phase 3
GSK made a £75m investment in manufacturing capacity for the Ellipta inhaler system as a second manufacturing site in the USA following Phase 2 of the programme.
The project included the conversion of an onsite catering facility into manufacturing space, the refurbishment of laboratory space and filling suites, together with the delivery of assembly, packing and filling lines as well as laboratory equipment.
G&T provided project controls support involving the creation and maintenance of the master schedule, estimate development, funding application support, cost management, change and risk management as well as the preparation of monthly reports.
Key Contacts
Client
GlaxoSmithKline (GSK)
Location
Zebulon, USA
